晚期非小细胞肺癌循环肿瘤DNA的混合捕获基因组分析
该研究对1552例晚期非小细胞肺癌患者进行基于混合捕获的62基因ctDNA检测,80%样本可检出ctDNA,其中86%存在至少一个可报告基因组改变。与组织基因组数据库比较显示各基因改变频率相似,但KRAS突变在组织中更常见、EGFR T790M在ctDNA中更常见。33例配对样本中,组织检出的改变64%可在ctDNA中检出。
要点
- 晚期NSCLC患者血液ctDNA混合捕获测序可检出临床相关基因组改变。
- ctDNA与组织检测的基因改变频率总体相似,但KRAS突变和组织中更常见、EGFR T790M在ctDNA中更常见。
- 配对样本中组织短变异78%、重排100%可在ctDNA中检出,但扩增仅16%。
核心结论
- 晚期NSCLC中ctDNA基因组分析可在相当比例病例检出临床相关基因组改变,多数组织检出的改变也可在配对ctDNA中检出。
- ctDNA检测可作为组织检测的补充方法,尤其在靶向治疗进展时可能有用。
研究设计与样本
- 对1552例非小细胞肺癌患者的血液ctDNA进行基于混合捕获的62基因基因组分析。
- 与包含21500例的组织基因组数据库进行比较分析。
- 对33例有ctDNA证据的患者进行时间匹配的ctDNA与组织样本比较。
主要发现
- 80%的样本检测到ctDNA证据,其中86%检出至少一个可报告基因组改变。
- 常见改变基因频率为TP53 59%、EGFR 25%、KRAS 17%。
- 与组织数据库比较各基因改变频率相似,但KRAS突变在组织更常见、EGFR T790M在ctDNA更常见(均p<0.0001)。
- 33例配对样本中,组织检出的基因组改变64%也在ctDNA中检出,包括短变异78%(58/74)和重排100%(4/4),但扩增仅16%(4/25)。
临床怎么用
- 晚期NSCLC可考虑血液ctDNA检测作为组织活检的补充,用于基因组分析。
- 靶向治疗进展时,血液ctDNA检测可能尤其有助于发现耐药相关改变如EGFR T790M。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genomic profiling informs selection of matched targeted therapies as part of routine clinical care in NSCLC. Tissue biopsy is the criterion standard; however, genomic profiling of blood-derived circulating tumor DNA (ctDNA) has emerged as a minimally invasive alternative. METHODS: Hybrid capture-based genomic profiling of 62 genes was performed on blood-based ctDNA from 1552 patients with NSCLC. RESULTS: Evidence of ctDNA was detected in 80% of samples, and in 86% of these cases, at least one reportable genomic alteration (GA) was detected. Frequently altered genes were tumor protein p53 gene (TP53) (59%), EGFR (25%), and KRAS (17%). Comparative analysis with a tissue genomic database (N = 21,500) showed similar frequencies of GAs per gene, although KRAS mutation and EGFR T790M were more frequent in tissue and ctDNA, respectively (both p < 0.0001), likely reflecting the use of liquid versus tissue biopsy after relapse during targeted therapy. In temporally matched ctDNA and tissue samples from 33 patients with evidence of ctDNA in their blood, 64% of GAs detected in tissue were also detected in ctDNA, including 78% of short variants (58 of 74) and 100% of rearrangements (four of four), but only 16% of amplifications (four of 25). CONCLUSIONS: Genomic profiling of ctDNA detected clinically relevant GAs in a significant subset of NSCLC cases. Most alterations detected in matched tissue were also detected in ctDNA. These results suggest the utility of ctDNA testing in advanced NSCLC as a complementary approach to tissue testing. Blood-based ctDNA testing may be particularly useful at the time of progression during targeted therapy.
引用
- Schrock AB, Welsh A, Chung JH, et al. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30368012. doi:10.1016/j.jtho.2018.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。